Strs Ohio Lowers Stake in MacroGenics, Inc. (NASDAQ:MGNX)

Strs Ohio reduced its holdings in shares of MacroGenics, Inc. (NASDAQ:MGNX) by 40.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 67,300 shares of the biopharmaceutical company’s stock after selling 45,100 shares during the period. Strs Ohio owned 0.11% of MacroGenics worth $647,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of MGNX. SG Americas Securities LLC bought a new stake in MacroGenics during the 3rd quarter valued at about $97,000. Principal Financial Group Inc. increased its stake in MacroGenics by 0.9% during the 3rd quarter. Principal Financial Group Inc. now owns 275,550 shares of the biopharmaceutical company’s stock valued at $1,284,000 after purchasing an additional 2,335 shares in the last quarter. Los Angeles Capital Management LLC bought a new stake in MacroGenics during the 3rd quarter valued at about $281,000. Barclays PLC increased its stake in MacroGenics by 15.2% during the 3rd quarter. Barclays PLC now owns 134,273 shares of the biopharmaceutical company’s stock valued at $624,000 after purchasing an additional 17,733 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA increased its stake in MacroGenics by 32.9% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 194,204 shares of the biopharmaceutical company’s stock valued at $905,000 after purchasing an additional 48,118 shares in the last quarter. 96.89% of the stock is owned by hedge funds and other institutional investors.

MacroGenics Trading Up 1.3 %

Shares of NASDAQ MGNX opened at $14.56 on Friday. The firm has a 50 day moving average of $16.73 and a 200 day moving average of $11.91. The firm has a market capitalization of $910.87 million, a price-to-earnings ratio of -91.00 and a beta of 2.09. MacroGenics, Inc. has a 12-month low of $4.29 and a 12-month high of $21.88.

MacroGenics (NASDAQ:MGNX) last announced its earnings results on Thursday, March 7th. The biopharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.49). The business had revenue of $10.72 million for the quarter, compared to the consensus estimate of $25.70 million. MacroGenics had a negative net margin of 15.42% and a negative return on equity of 88.49%. During the same quarter last year, the firm posted $0.21 earnings per share. Sell-side analysts predict that MacroGenics, Inc. will post -2.7 EPS for the current year.

Insider Activity at MacroGenics

In related news, SVP Ezio Bonvini sold 13,316 shares of the business’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $15.00, for a total transaction of $199,740.00. Following the completion of the sale, the senior vice president now directly owns 74,668 shares in the company, valued at $1,120,020. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other MacroGenics news, VP Jeffrey Stuart Peters sold 16,124 shares of MacroGenics stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $17.22, for a total transaction of $277,655.28. Following the transaction, the vice president now owns 8,895 shares of the company’s stock, valued at $153,171.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Ezio Bonvini sold 13,316 shares of MacroGenics stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $15.00, for a total transaction of $199,740.00. Following the transaction, the senior vice president now directly owns 74,668 shares in the company, valued at approximately $1,120,020. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 80,835 shares of company stock worth $1,276,588. 11.30% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of research firms have weighed in on MGNX. JMP Securities restated a “market outperform” rating on shares of MacroGenics in a research note on Thursday, April 4th. TD Cowen upgraded shares of MacroGenics from a “hold” rating to a “buy” rating in a research note on Tuesday, April 9th. TheStreet lowered shares of MacroGenics from a “c” rating to a “d” rating in a research note on Thursday, March 7th. BTIG Research lifted their price target on shares of MacroGenics from $12.00 to $24.00 and gave the stock a “buy” rating in a research note on Monday, March 4th. Finally, Barclays lifted their price target on shares of MacroGenics from $12.00 to $23.00 and gave the stock an “overweight” rating in a research note on Thursday, February 29th. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $18.00.

MacroGenics Profile

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.